Recent landmark studies presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference have revealed transformative advances in lung cancer therapy. AstraZeneca's FLAURA2 trial demonstrated that combining Tagrisso with chemotherapy reduced death risk by 23% in EGFR-mutant advanced non-small cell lung cancer (NSCLC). Concurrently, the bispecific antibody-drug conjugate iza-bren (BL-B01D1) achieved a 100% response rate in a Phase II trial for EGFR-mutated NSCLC, signaling potent clinical efficacy. Additional evidence from the ACROSS 2 Phase III trial showed aumolertinib plus chemotherapy significantly improved progression-free survival in EGFR-mutant patients harboring tumor suppressor gene alterations. Summit Therapeutics reported mixed efficacy of ivonescimab combined with chemotherapy between Chinese and Western patient cohorts, complicating regulatory approval strategies. Collectively, these studies underscore a dynamic shift towards combination regimens and precision antibody therapeutics that could redefine standard-of-care for lung cancers driven by EGFR mutations and other oncogenic alterations.